Musely / The Acne Cream

What it is

The Acne Cream is a compounded prescription cream sold by Musely through an online consultation, at $30 a month starting with a two-month supply. The published Zap formula is tretinoin 0.015%, clindamycin 0.75%, niacinamide 4% and azelaic acid 2%. Directions are a pea-sized amount once daily in the evening.

It is the cheapest product we have looked at from this brand and, in its core construction, the most defensible. It is also the one with the finding that reaches furthest beyond the individual buyer.

The combination is right

It is worth stating plainly, because the rest of this review is critical. Pairing a topical retinoid with a topical antibiotic is not a shortcut or a compounding gimmick — it is one of the fixed-dose combinations the American Academy of Dermatology strongly recommends for acne. The retinoid addresses the comedone; the antibiotic addresses the organism and the inflammation. They work on different parts of the pathology and they are meant to be used together.

Niacinamide at 4% is also a genuinely good inclusion at a genuinely correct dose. It damps sebum output, it is anti-inflammatory, and it supports the barrier at exactly the moment a retinoid is stressing it. This is the second properly dosed active we have found across the Musely range.

The specific gap is benzoyl peroxide

The retinoid is in the formula for efficacy. Benzoyl peroxide does something different and additional: it is the agent that suppresses the emergence of resistant organisms while an antibiotic is being used.

The comparison that makes this concrete is a sixteen-week study in mild to moderate acne. Counts of clindamycin-resistant C. acnes stayed at or below baseline in patients using a fixed clindamycin-with-benzoyl-peroxide gel. In patients using clindamycin gel alone, resistant counts rose to more than sixteen times baseline over the same period.

This is not a hypothetical harm to a distant third party. Resistant C. acnes on your own face is why a topical antibiotic that worked in month two stops working in month eight, and why the next antibiotic you are offered may work less well. It is also, cumulatively, a public health matter — which is why every major dermatology guideline has moved in the same direction on it.

The second half of the problem is duration. Topical antibiotic use is supposed to be time-limited and reassessed rather than continued indefinitely. A monthly subscription is a structure with no reassessment point in it — the default behaviour is that it keeps arriving.

Azelaic acid at 2% is not azelaic acid

Azelaic acid is a genuinely good acne active. It is antibacterial, it is anti-inflammatory, it normalises follicular keratinisation, and it fades the post-inflammatory marks that are often what people actually mind. It does those things at 15% and 20%, which are the strengths it is prescribed at.

Here it is at 2% — a tenth of the lower therapeutic dose — and it is named on the product page as one of four actives targeting inflammation and clogged pores. If you are buying this partly for the azelaic acid, you should know that at this concentration it is not going to deliver what azelaic acid delivers.

The tretinoin pattern, across three products

This is the third Musely product we have assessed and the third time tretinoin has appeared below the concentration range its trials are run at. Having a register makes that pattern visible in a way a single review would not.

There is a real argument for compounding a retinoid low in teledermatology, and it deserves airing rather than dismissing. Adherence predicts acne outcomes more reliably than dose does. A 0.015% tretinoin that someone tolerates and uses for nine months will beat a 0.05% that they abandon in week three with a peeling face. Low-and-slow is a legitimate strategy, and it is the norm across this category rather than something unique to Musely.

Our objection is not that the dose is low. It is that the rationale is never stated, the concentration is not published where you buy the product, and there is no described path to titrating upward once tolerance is established. Presented as a deliberate starting dose with a plan attached, 0.015% is defensible. Presented as an unstated number you have to find in a help centre, it is not.

The 91% figure

The headline claim is that 91% of patients participating in self-report efficacy data saw improvement by day 30 — the highest of the three figures we have examined from this brand, and produced by the same method as the other two.

Acne is a particularly poor fit for uncontrolled self-report. It fluctuates with the menstrual cycle, with stress and with season; it improves for many people simply from starting any consistent routine; and thirty days is short enough that a natural trough can be mistaken for a treatment effect. The brand's own page says most patients see initial improvement at six to eight weeks, which sits awkwardly beside a 91% figure measured at thirty days.

If you are going to use it

• ▸Buy a benzoyl peroxide wash and use it in the morning. This is the single most valuable thing you can do with this product and it costs very little.
• ▸Ask the prescriber how long the clindamycin is for and what happens afterwards. Topical antibiotics should be reassessed, not renewed by default.
• ▸Confirm which actives your tube actually contains — the prescriber may omit some at their discretion.
• ▸Wear SPF 30 or higher daily. The product page is right about this and it is not optional with a retinoid.
• ▸Give it eight to twelve weeks. Judging a retinoid at thirty days will mislead you in both directions.
• ▸Do not add a separate exfoliating acid on top. The retinoid is already doing that job and the barrier will fail before the acne does.
• ▸Do not use it if there is any chance you are pregnant.

Where we stand

This is the best of the three Musely products we have assessed, and it scores highest of them. The core combination is guideline-endorsed rather than invented, one of the four actives is dosed exactly right, the price is fair, and the treatment area is small enough that the unpublished container size matters less than it does on a body product.

What holds it at a conditional verdict is that a product built around a topical antibiotic omits the one agent whose job is to keep that antibiotic working, sells it on a subscription with no reassessment point, and pads the active list with an azelaic acid at a tenth of its working dose. Two of those are fixable by the buyer in an afternoon. The third is a formulation decision only the brand can make.